Caratterizzazione del bersaglio di un nuovo farmaco antitubercolare: validazione genetica e prove di espressione di Rv0579 isolato da Mycobacterium tuberculosis

This research is part of the project “More Medicines for Tuberculosis” (MM4TB, EC-VII framework program), whose goals are the validation of at least five new drug targets pharmacologically and the discovery of at least one family of candidate antitubercular drugs.Among these molecules, we demonstrated that the tienopirimidine (TP) compound TP053 is a prodrug, actived by the thioredoxin-like enzyme Rv2466c, and presumably targeting Rv0579, an highly conserved hypothetical protein.The genetic validation of Rv0579 as the possible cellular target of TP053 prodrug is provided in this work in addition to the expression trials of this target.